This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Yavuz, D. Articles by Akalln, S. Search for Related Content PubMed PubMed Citation Articles by Yavuz, D. Articles by Akalln, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines High Blood Pressure Hazardous Substances DB ENALAPRIL MALEATE LOSARTAN POTASSIUM NITRIC OXIDE Social Bookmarking                         What's this?

Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients

Section of Endocrinology and Metabolism, Marmara University Medical School, dyavuz{at}tnn.net

Mehmet Koç

Section of Nephrology, Marmara University Medical School

Ahmet Toprak

Department of Internal Medicine, Marmara University Medical School

Ihsan Akpnar

Department of Radiology, Marmara University Medical School

Ayliz Veliolu

Department of Biochemistry, Marmara University Medical School, Istanbul, Turkey

Oguzhan Deyneli

Section of Endocrinology and Metabolism, Marmara University Medical School

Goncagül Haklar

Department of Biochemistry, Marmara University Medical School, Istanbul, Turkey

Sema Akalln

Section of Endocrinology and Metabolism, Marmara University Medical School

Objective

Disturbed endothelial function is closely associated with hyperinsulinaemia and insulin resistance in essential hypertension. The aims of this study were:

1) to evaluate whether the two alternative drugs, angiotensin-converting enzyme (ACE) inhibitors and Angiotensin II (Ang II) antagonists, had comparable effects on glucose metabolism and endothelial function.

2) to determine whether they improve endothelial dysfunction through modulating insulin resistance and oxidative stress.

Study design and methods

Study design and methods

Essential hypertensive patients were randomised into two groups: Twelve (nine patients in final analysis) patients were given enalapril (enalapril group), and twelve (nine patients in final analysis) were given losartan (losartan group). Twelve sex- and age-matched normotensive volunteers were included as controls. Before and after six months of treatment, endothelial function, insulin sensitivity and lipid peroxidation (TBARs) and NO metabolites (NOx) were evaluated.

Results

Endothelial function, measured as flow mediated dilatation (FMD), was improved in both of the treatment groups (p=0.0001). Calculated insulin sensitivity index also improved in the enalapril-treated group (p=0.05) but not in the losartan-treated group, compared with baseline levels. TBARS values decreased significantly in the enalapril group compared with baseline levels (p<0.001). FMD was positively correlated with insulin sensitivity index (r=0.32, p<0.05) and NOx levels (r=0.39, p=0.01) and negatively correlated with TBARS levels (r=-0.53, p=0.0002) in hypertensive patients.

Conclusion

Inhibition of the renin-angiotensin system, either with ACE inhibitors or AT₁-receptor blockers improves endothelial dysfunction. ACE inhibition has prominent effects on improving insulin sensitivity and decreasing oxidative stress in essential hypertensive patients.

Key Words: hypertension • angiotensin-converting enzyme inhibitors • angiotensin II receptor antagonists • insulin resistance • vascular endothelium • oxidative stress

Journal of Renin-Angiotensin-Aldosterone System, Vol. 4, No. 3, 197-203 (2003)
DOI: 10.3317/jraas.2003.032


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. J. Katovich, J. L. Grobe, M. Huentelman, and M. K. Raizada Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension Exp Physiol, May 1, 2005; 90(3): 299 - 305. [Abstract] [Full Text] [PDF]